Assessing user fees under the Biosimilar User Fee Amendments of 2017
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Guidance for industry
- Contributor(s):
- United States. Department of Health and Human Services, issuing body. United States. Food and Drug Administration, issuing body. Center for Biologics Evaluation and Research (U.S.), issuing body. Center for Drug Evaluation and Research (U.S.), issuing body.
- Publication:
- Silver Spring, MD : Center for Drug Evaluation and Research, January 2020
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Biosimilar Pharmaceuticals -- economics Drug Development -- economics United States United States. Department of Health and Human Services. United States. Food and Drug Administration.
- Genre(s):
- Technical Report
- Copyright:
- The National Library of Medicine believes this item to be in the public domain. (More information)
- Extent:
- 1 online resource (1 PDF file (16 pages, 5 unnumbered pages)).
- Edition:
- Revision 1
- NLM Unique ID:
- 101767621 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101767621